Is imaging of tau the preferable marker of cognitive impairment in AD?
Yes: Panteleimon Giannakopoulos, Switzerland

Department of Psychiatry, University of Geneva School of Medicine, 2, ch Petit Bel-Air, 1225 Geneva, Switzerland, tel: 0041223055006, fax: 0041223055044

Early clinic-pathological studies demonstrated that the two cardinal lesions associated with Alzheimer disease (AD), neurofibrillary tangles (NFT) and amyloid deposits, have a differential impact on cognition both at early and late stages of the neurodegenerative process. In contrast to β-amyloid (Aβ) deposition that occurs diffusely in the human brain over 60 years of age, NFT formation follows hierarchical schemes of regional and cellular vulnerability affecting first the entorhinal cortex and parahippocampal formation before moving in adjacent neocortical association areas. Long before the emergence of novel imaging techniques, it was clear that Aβ deposits correlate very weekly with cognition and downstream neurodegenerative biomarkers. In contrast, NFT and associated synaptic loss is strictly related to the loss of cognitive functions not only at late but also at early stages of AD. The last decade was characterized by the exponential increase of knowledge in the field of AD predictive biomarkers and, most importantly, characterization of tracers for β-amyloid (Aβ). It is now widely acknowledged that amyloid deposits in positron emission tomography (PET) with Pittsburg compound B (PiB; a marker of Aβ fibrillar deposits) precede dementia by 5-10 years, and PiB burden inversely correlates with concentration of Aβ42 in the cerebrospinal fluid. However, increased PiB burden was reported in nearly 20% to 30% of controls in the general population pointing to the fact that Aβ deposition is not sufficient to cause cognitive decline in AD. Moreover, the rate of Aβ accumulation is not related to neurodegeneration at baseline and only 8% of controls display both decreased hippocampal volume and increased PiB signal. According to Jack’s model, all of the aforementioned markers become positive well before dementia onset, and the ones related to amyloid pathology already reach their plateau at the time of first cognitive deficits. More recently, selective tau tracers became available for clinical research. Although a PiB equivalent is not yet ready for tau imaging, the recent development of tau tracers with higher selectivity, reduced non-specific binding and improved tracer kinetics compared to the first molecules raise increasing expectations among the scientific community. Given the tight association between tau deposition, cognition and neurodegeneration, and unlike Aβ imaging, tau imaging will be essential for assessing disease progression. Furthermore, they may help to resolve the controversy about the temporal sequence of tau pathology in AD. The new diagnostic criteria by Dubois and collaborators consider that the development of tau pathology, at least under its fibrillar forms, is a late phenomenon in AD dependent, at least partly, on the Aβ deposition in prodromal states. Recent contributions showed that tau-related markers (but also structural MRI changes) might become positive in the absence of PiB deposits mainly in preclinical cases. Ultimately, tau imaging will provide the tool to change the landscape and explore whether or not presymptomatic administration of anti-Aβ therapy impacts on the progression of tau pathology that determines the clinical expression of AD.